CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
Taipei, Taiwan and 93 other locations
in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...
Phase 3
Taipei, Taiwan and 131 other locations
in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, wh...
Phase 3
Taipei City, Taiwan and 207 other locations
The primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from base...
Phase 2
Taipei, Taiwan and 44 other locations
cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian...
Phase 3
Taipei, Taiwan and 148 other locations
following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based...
Phase 3
Taipei, Taiwan and 237 other locations
and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary perito...
Phase 3
Taipei, Taiwan and 226 other locations
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer...
Phase 1, Phase 2
Taipei, Taiwan and 38 other locations
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Com...
Phase 2
Taipei, Taiwan and 92 other locations
in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended do...
Phase 1
Taipei, Taiwan and 12 other locations
Clinical trials
Research sites
Resources
Legal